Search results
Results from the WOW.Com Content Network
Ionis Pharmaceuticals, Inc. is a biotechnology company based in Carlsbad, California, that specializes in discovering and developing RNA-targeted therapeutics.The company has three commercially approved medicines: Spinraza (), Tegsedi (), and Waylivra (Volanesorsen), and has four drugs in pivotal studies: tominersen for Huntington's disease (together with Roche), tofersen for SOD1-ALS, AKCEA ...
Clinical trial number NCT04136184 for "NEURO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy" at ClinicalTrials.gov
Ionis Pharmaceuticals Stock Price And Volume Action Ionis Pharmaceuticals (NASDAQ:IONS) is currently down 17.47% to a price of $46.29. Tuesday the stock has been traded at a volume of 2.55 million ...
US FDA approves Ionis Pharma's genetic disorder drug. Mariam Sunny and Kamal Choudhury. December 19, 2024 at 2:18 PM. ... "We will be planning to price olezarsen as you would, a first-time ...
At that time, only Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (formerly Isis Pharmaceuticals until December 2015) [2] was conducting significant research with this technology. Antisense is a short span of oligonucleotides – modified DNA structures ranging from about 12-24 bases that selectively bind to specific RNA.
The U.S. Food and Drug Administration (FDA) on Thursday approved Ionis Pharmaceuticals and partner AstraZeneca's drug to treat nerve damage caused by a life-shortening rare disease. The drug ...
This pharmacology -related article is a stub. You can help Wikipedia by expanding it.
For premium support please call: 800-290-4726 more ways to reach us